

# Kayentis

Dedicated to eCOA and patient engagement

## Kayentis, a global expert in eCOA, is strengthening its US presence

kayentis · Tuesday, June 19th, 2018

**Kayentis, expert in eCOA, is strengthening its presence in the US and opening offices in Boston. Guillaume Juge, Kayentis CEO explains the rationale for this expansion in the US.**



## Why is Kayentis opening new offices in Boston and expanding its staff?

*Our company's business development and competitive strategy includes the rapid growth of our presence in the United States.*

*The opening of our Boston office reinforces our customer-focused approach. To ensure high-quality support for clinical studies we want to remain close to our clients with a presence wherever it is needed, in Europe, Asia, and the US.*

## Why is now the time for this increased presence in the US?

*We significantly increased our US footprint last year with projects with new clients including pharma, biotech, and CROs. This increase in activity*

*will continue to grow over the coming year.*

*Furthermore, we've spent time to ensure effective links between our US and European operations, and now have everything in place to ensure a consistent and harmonized expansion in the US.*

## **What is your development strategy in the US?**

*Our ambition is to become the 3<sup>rd</sup> largest eCOA player globally and the best in terms of quality of service.*

*To support our US development and activities, the US team will grow quickly in the coming months and years, as has been the case for our teams in Europe.*

*In parallel, we will continue to innovate and improve our eCOA solution, Clin'form3 Suite, to deliver best-in-class eCOA data capture solutions. We strive to provide customers, clinical sites, and patients the most efficient, easy-to-use, and comprehensive solutions. We aim to be a leading reference in innovation in eCOA market through the quality of our solutions, services, and databases that we provide to Sponsors and CROs.*

**We are committed to contributing to the reliability of clinical research, and to helping to improve human health.**

*Guillaume JUGE, CEO - Kayentis*

This entry was posted on Tuesday, June 19th, 2018 at 12:27 pm and is filed under [Kayentis spirit](#), [Kayentis news](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.